A Double-blind, Placebo Controlled, Crossover, Ascending Single Dose Safety Tolerability, Pharmacokinetic and Pharmacodynamic Study of Neu-120 in Patients With Advanced Phase Idiopathic Parkinson's Disease With Levodopa Induced Dyskinesia

The purpose of this study is to determine the safety, tolerability, pharmacokinetic and pharmacodynamic effects of single doses of Neu-120 in Parkinson's disease patients with levodopa-induced dyskinesia.

开始日期2008-03-01

申办/合作机构

Neurim Pharmaceuticals Ltd.

100 项与 Neu-120 相关的临床结果

登录后查看更多信息

100 项与 Neu-120 相关的转化医学

登录后查看更多信息

100 项与 Neu-120 相关的专利（医药）

登录后查看更多信息

项与 Neu-120 相关的文献（医药）

2010-02-01·European Journal of Clinical Pharmacology3区 · 医学

Novel therapeutic strategies in Parkinson’s disease

3区 · 医学

Review

作者: Laszlo Vecsei ; Peter Klivenyi

PD is a neurodegenerative disorder triggered by genetic and/or environmental factors and the pathological processes begin many years before motor symptom manifestation. Several drugs are available to treat PD, but there are still many aspects of the disease that have not been well addressed. These include nonmotor symptoms, disease progression, and preventing levodopa-induced motor complications. Besides the concept of continuous dopaminergic stimulation, the benefit of which has not been proved in clinical settings (see the STRIDE-PD trial), the nondopaminergic drugs offer promising alternatives to dopaminergic medication. However, modification and further development of dopaminergic molecules may provide significant symptomatic improvement and improved quality of life. In this review, we summarized new treatments that are in the pipeline, with patients being recruited for clinical trials. Among the compounds being studied are well-known ones (e.g., folic acid or methylphenidate), which have been used in other diseases, and newly developed drugs with known mode of action (e.g., the dopamine agonist aplindore) or compounds with completely new mechanisms, which have not yet been used in clinical settings (e.g., levetiracetam or Neu 120). A major breakthrough in treating Parkinson's disease cannot be expected with molecules from the first two cases, whereas significant clinical benefits can be predicted with the drugs in the last group. However, without these large-scale, well-designed, multicenter trials, the promising preclinical results cannot be directly adopted in patient care. Hopefully, some of these trials will end soon with positive results, and certain drugs will become available with which to treat PD patients, although still many aspects (e.g., the most problematic one, the question of neuroprotection) still need to be addressed.

100 项与 Neu-120 相关的药物交易

登录后查看更多信息